Literature DB >> 3151939

Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure.

P Kincaid-Smith1, K F Fairley, M Kloss.   

Abstract

The clinical features in 12 women with a circulating coagulation inhibitor (lupus 'anticoagulant') were studied and correlated with findings in 22 renal biopsies in these patients. Four of 12 women had serological evidence of systemic lupus. Only two of 23 pregnancies in these women were successful. Lesions in all biopsies were remarkably similar. Seven biopsies taken during or soon after pregnancy showed acute fibrinoid lesions. 'Acute' lesions consisted of fibrin thrombi in glomeruli arterioles and arteries and double contours in glomerular capillary walls. Biopsies carried out remote from pregnancy in these seven patients showed persisting double contours in glomeruli together with narrowing of arteries due to recanalizing thrombi and cellular intimal proliferation. All other biopsies showed similar lesions. The lesions were essentially the same as those of thrombotic microangiopathy and those described previously in post-partum renal failure. Renal function was severely impaired in four patients and showed moderate impairment in two patients at the time that acute thrombotic lesions were demonstrated in glomeruli. Renal function in two patients improved during plasma exchange therapy. Because all biopsies showed either acute, healing or healed, thrombotic lesions, it is proposed that these lesions are characteristic of the renal findings in patients with a lupus 'anticoagulant'. In all but two cases the acute lesions were seen during or soon after pregnancy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3151939

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  18 in total

Review 1.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

2.  Addison's disease, hypertension, renal and hepatic microthrombosis in 'primary' antiphospholipid syndrome.

Authors:  S Inam; K Sidki; A R al-Marshedy; R Judzewitsch
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

Review 3.  Renal involvement in antiphospholipid syndrome.

Authors:  Francisco Vileimar Andrade de Azevedo; Diego Germano Maia; Jozelio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  Rheumatol Int       Date:  2018-05-05       Impact factor: 2.631

Review 4.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 5.  Is there a microangiopathic antiphospholipid syndrome?

Authors:  Ronald A Asherson; Sylvia S Pierangeli; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

Review 6.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 7.  Renal involvement in primary antiphospholipid syndrome.

Authors:  Carmelita Marcantoni; Carmela Emmanuele; Francesco Scolari
Journal:  J Nephrol       Date:  2016-05-19       Impact factor: 3.902

Review 8.  Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

Authors:  Maria G Tektonidou
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 9.  Accelerated hypertension and nephroangiosclerosis associated with antiphospholipid syndrome. Report of two cases and review of the literature.

Authors:  J M Durand; P Lefevre; G Kaplanski; P Casanova; J Soubeyrand
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

10.  Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases.

Authors:  Hui Zheng; Yi Chen; Wen Ao; Yan Shen; Xiao-wei Chen; Min Dai; Xiao-dong Wang; Yu-cheng Yan; Cheng-de Yang
Journal:  Arthritis Res Ther       Date:  2009-06-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.